Shell Asset Management Co. Decreases Stake in Amedisys, Inc. (NASDAQ:AMED)

Shell Asset Management Co. reduced its stake in Amedisys, Inc. (NASDAQ:AMEDGet Rating) by 12.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,958 shares of the health services provider’s stock after selling 289 shares during the quarter. Shell Asset Management Co.’s holdings in Amedisys were worth $337,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Montag A & Associates Inc. purchased a new position in shares of Amedisys in the 1st quarter valued at approximately $2,858,000. Mutual of America Capital Management LLC raised its position in Amedisys by 2.0% during the 1st quarter. Mutual of America Capital Management LLC now owns 29,729 shares of the health services provider’s stock worth $5,122,000 after buying an additional 570 shares during the last quarter. Signaturefd LLC raised its position in Amedisys by 295.8% during the 1st quarter. Signaturefd LLC now owns 376 shares of the health services provider’s stock worth $65,000 after buying an additional 281 shares during the last quarter. SG Americas Securities LLC raised its position in Amedisys by 36.8% during the 1st quarter. SG Americas Securities LLC now owns 9,992 shares of the health services provider’s stock worth $1,722,000 after buying an additional 2,690 shares during the last quarter. Finally, Park Avenue Securities LLC raised its position in Amedisys by 12.8% during the 1st quarter. Park Avenue Securities LLC now owns 6,250 shares of the health services provider’s stock worth $1,077,000 after buying an additional 710 shares during the last quarter. 90.47% of the stock is owned by hedge funds and other institutional investors.

Amedisys Trading Down 0.4 %

Shares of AMED opened at $121.17 on Friday. Amedisys, Inc. has a 52-week low of $101.61 and a 52-week high of $203.84. The company has a quick ratio of 0.92, a current ratio of 0.92 and a debt-to-equity ratio of 0.43. The firm’s fifty day moving average is $118.38 and its two-hundred day moving average is $134.64. The stock has a market cap of $3.93 billion, a PE ratio of 28.24, a price-to-earnings-growth ratio of 2.39 and a beta of 0.95.

Amedisys (NASDAQ:AMEDGet Rating) last announced its earnings results on Wednesday, July 27th. The health services provider reported $1.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.24. Amedisys had a net margin of 6.33% and a return on equity of 17.81%. The company had revenue of $557.89 million for the quarter, compared to analysts’ expectations of $583.12 million. During the same quarter in the previous year, the company posted $1.69 EPS. The firm’s quarterly revenue was down 1.1% on a year-over-year basis. Research analysts forecast that Amedisys, Inc. will post 5.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Stifel Nicolaus assumed coverage on shares of Amedisys in a research report on Tuesday, June 28th. They set a “hold” rating and a $128.00 price target for the company. Bank of America lowered shares of Amedisys from a “neutral” rating to an “underperform” rating and reduced their price target for the stock from $145.00 to $102.00 in a research report on Tuesday, June 21st. UBS Group cut shares of Amedisys from a “neutral” rating to a “sell” rating and dropped their price objective for the stock from $145.00 to $95.00 in a research note on Tuesday. Raymond James dropped their price objective on shares of Amedisys from $200.00 to $180.00 in a research note on Friday, April 29th. Finally, SVB Leerink dropped their price objective on shares of Amedisys from $117.00 to $107.00 and set a “market perform” rating on the stock in a research note on Tuesday, June 21st. Two research analysts have rated the stock with a sell rating, five have given a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $160.63.

Insiders Place Their Bets

In other Amedisys news, insider Denise M. Bohnert sold 557 shares of Amedisys stock in a transaction on Thursday, June 23rd. The shares were sold at an average price of $115.00, for a total transaction of $64,055.00. Following the sale, the insider now owns 11,850 shares of the company’s stock, valued at approximately $1,362,750. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 2.10% of the stock is currently owned by corporate insiders.

About Amedisys

(Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Recommended Stories

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.